Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy

OBJECTIVES:

• To screen serum specimens using a high throughput protein profiling platform that tests for the highest number of known biomarkers (detectable by antibodies) that could be predictors of response to interferon treatment, autoimmunity, and disease outcome in patients with high-risk melanoma undergoing high-dose interferon (IFNa2b) therapy .
• To compare soluble factors across all patients at each time point (baseline and during therapy).
• To compare pre-therapy vs post-therapy serum samples from these patients.
• To assess the kinetics of soluble factors' appearance, persistence, and disappearance during the 12 months of therapy.
• To assess whether the amount of specific soluble factors in the pre-therapy sample is predictive of response independent of therapy.
• To correlate statistically significant factors with S100 and autoimmunity in these patients.
• To confirm the data obtained with the Luminex technology.

OUTLINE: Patients are stratified according to survival (< 2 years vs > 5 years).

Blood samples collected from patients enrolled in E-1694 are analyzed using high throughput protein profiling by ELISA to compare changes in levels of putative biomarkers of interferon alfa-2b, including cytokines and paired receptors, chemokines, cell adhesion molecules, metalloproteinases, angiogenic markers, growth factors, soluble receptors, signal transduction molecules, hormones, and other biomarkers of disease and dysregulated immune processes, at baseline and during therapy.

DISEASE CHARACTERISTICS:

• Diagnosis of high-risk melanoma
• Receiving interferon alfa-2b therapy in arm II of clinical trial E-1694

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics